McGill University Medical Podcast Series
Dr. Richard Menzies and Dr. Jonathan Campbell - 4 months of Rifampin for latent TB


Published online: 13 February 2019
1 Faculty of Medicine, McGill University, Montréal, Canada.
Corresponding Author: Russel Yanofsky, email russ.yanofsky@gmail.com.

Episode 4

In this episode, we're joined by Dr. Richard Menzies and Dr. Jonathan Campbell from the McGill Respiratory Epidemiology and Clinical Research Unit to discuss the results of their multi-center RCT comparing 4 months of rifampin to 9 months of isoniazid for the treatment of latent TB. Their findings are outlined in two papers, entitled " Four Months of Rifampin or Nine Months of Isoniazid for Latent TB in Adults" and "Safety and Side Effects of Rifampin Versus Isoniazid in Children" published in the August 2018 issue of the New England Journal of Medicine.


Articles:
  1. Diallo T, Adjobimey M, Ruslami R, Trajman A, Sow O, Obeng Baah J, et al. Safety and Side Effects of Rifampin versus Isoniazid in Children. N Engl J Med. 2018 Aug 2;379(5):454–63.10.1056/NEJMoa1714284
  2. Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, et al. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. N Engl J Med. 2018 Aug 2;379(5):440–53.10.1056/NEJMoa1714283